Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-05-22
2011-12-06
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S391100, C530S391300, C424S130100, C424S133100, C424S141100, C424S178100
Reexamination Certificate
active
08071730
ABSTRACT:
The present invention relates to novel isolated antibodies, derived compounds, and functional isolated antibody fragments, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo and obtained by functional screening.More particularly, the present invention relates to the 6F4 antibody, specific to the JAM-A protein, as well as its use for the treatment of cancer. Pharmaceutical compositions composed of these antibodies are also covered.
REFERENCES:
patent: 6235883 (2001-05-01), Jakobovits et al.
patent: 6677436 (2004-01-01), Sato et al.
patent: WO 2005/060457 (2005-07-01), None
patent: WO 2006/008076 (2006-01-01), None
patent: WO 2007127476 (2007-11-01), None
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Mac Callum, Martin and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained by shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 151-162.
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Lefranc, “Unique database numbering system for immunogenetic analysis,”Immunology Today, Nov. 1997, p. 509, vol. 18 No. 11.
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,”Developmental and Comparative Immunology, 2003, pp. 55-77, vol. 27, Elsevier Science Ltd.
Rulz et al., IMGT gene identification and Colliers de Perles of human immunoglobulins with known 3D structures,Immunogenetics, 2002, vol. 53, pp. 857-883, Springer-Verlag.
Kaas et al., “IMGT Colliers de Perles: Standardized Sequence-Structure Representations of the IgSF and MhcSF Superfamily Domains,”Current Bioinformatics, 2007, vol. 2, pp. 21-30, Bentham Science Publishers Ltd.
Kaas et al., “IMGT/3Dstructure-DB and IMGT/StructuralQuery, a database and a tool for immunoglobulin, T cell receptor and MHC structural data,”Nucleic Acids Research, 2004, pp. D208-D210, vol. 32, Oxford University Press.
Smith et al., “Comparison of Biosequences,”Advances in Applied Mathematics, 1981, pp. 482-489, vol. 2, Academic Press, Inc.
Needleman et la., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,”J. Mol. Biol., 1970, pp. 443-453, vol. 48, Elsevier, BV.
Pearson et al., “Improved tools for biological sequence comparison,”Proc. Natl. Acad. Sci. USA, Apr. 1988, pp. 2444-2448, vol. 85, Elsevier Science BV.
Tatusova et al., “Blast 2 Sequences, a new tool for comparing protein and nucleotide sequences,”FEMS Microbiology Letters, 1999, pp. 247-250, vol. 174.
Skerra, “Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties,”Reviews in Molecular Biotechnology, 2001, pp. 257-275, vol. 74, Elsevier Science BV.
Kohl et al., “Designed to be stable: Crystal structure of a consensus ankyrin repeat protein,” PNAS, Feb. 18, 2003, pp. 1700-1705, vol. 100, No. 4, U.S. National Academy of Sciences.
Bes et al., “PIN bodies: A new class of antibody-like proteins with CD4 specificity derived from the protein inhibitor of neuronal nitric oxide synthase,”Biochemical and Biophysical Research Communications, 2006, pp. 334-344, vol. 343, Elsevier Inc.
Nicaise et al., “Affinity transfer by CDR grafting on a nonimmunoglobulin scaffold,”Protein Science, 2004, pp. 1882-1891, vol. 13, Cold Spring Harbor Laboratory Press, downloaded form www.proteinscience.org.
Bes et al., “Efficient CD4 binding and immunosuppressive properties of the 13B8.2 monoclonal antibody are displayed by its CDR-H1-derived peptide CB1,”FEBS Letters, 2001, pp. 67-74, vol. 508, Elsevier Science B.V.
Verhoeyen et al., “Engineering of Antibodies,”BioEssays, Feb./Mar. 1998, pp. 74-78, vol. 8, No. 2, Wiley Interscience.
Verhoeyen et al., “Reshaping Human Antibodies: Grafting an antilysozyme Activity,”Science, Mar. 25, 1988, pp. 1534-1536, vol. 239, downloaded from www.sciencemag.org.
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,”Nature, May 29, 1986, pp. 522-525, vol. 321, Nature Publishing Group.
Riechmann et al., “Reshaping human antibodies for therapy,”Nature, Mar. 24, 1988, pp. 323-327, vol. 332, Nature Publishing Group.
Singer et al., “Optimal Humanization of 1B4, an Anti-CD18 Murine Monoclonal Antibody, Is Achieved by Correct Choice of Human V-Region Framework Sequences,”The Journal of Immunology, Apr. 1, 1993, pp. 2844-2857, vol. 150, No. 7,The American Association of Immunologists.
Mountain et al., “Engineering Antibodies for Therapy,”Biotechnology and Genetic Engineering Reviews, Dec. 10, 1992, pp. 1-142, vol. 10, Intercept Ltd.
Junghans et al., “Advanced generation anti-CEA designer T cells for adenocarcinoma therapy,”Proceedings of the American Association for Cancer Research, Apr. 2006, #1183, p. 280, vol. 47, XP001245692.
Bebbington et al., “High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker,”Bio/Technology, Feb. 1992, pp. 169-175, vol. 10.
Kostrewa et la., “X-ray structure of junctional adhesion molecule: structural basis for homophilic adhesion via a noval dimerization motif,”The EMBO Journal, 2001, pp. 4391-4398, vol. 20 No. 16, European Molecular Biology Organization.
Prota et al., “Crystal structure of human junctional adhesion molecule 1: Implications for reovirus binding,”PNAS, Apr. 29, 2003, pp. 5366-5371, vol. 100, No. 9, U.S. National Academy of Sciences.
Bazzoni et al., “Homophilic Interaction of Junctional Adhesion Molecule,”The Journal of Biological Chemistry, Oct. 6, 2000, pp. 30970-30976, vol. 275 No. 40, The American Society for Biochemistry and Molecular Biology, Inc.
Liu et al., “Human junction adhesion molecule regulates tight junction resealing in epithelia,”Journal of Cell Science, 2000, pp. 2363-2374, vol. 113, The Company of Biologists Limited.
Ebnet et al., “Junctional Adhesion Molecule Interacts with the PDZ Domain-containing Proteins AF-6 and ZO-1,”The Journal of Biological Chemistry, 2000, pp. 27979-27988, vol. 275 No. 36, The American Society for Bio
Bes Cédric
Corvaia Nathalie
Goetsch Liliane
Haeuw Jean-François
Buchanan & Ingersoll & Rooney PC
Gussow Anne M.
Pierre Fabre Medicament
LandOfFree
Anti-JAM-A antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-JAM-A antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-JAM-A antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4307329